-DOCSTART- -X- O
Influenza -X- _ O
viruses -X- _ O
cause -X- _ O
annual -X- _ O
seasonal -X- _ O
epidemics -X- _ O
and -X- _ O
occasional -X- _ O
pandemics -X- _ O
of -X- _ O
human -X- _ B-Patient
respiratory -X- _ I-Patient
disease. -X- _ I-Patient
Influenza -X- _ O
virus -X- _ O
infections -X- _ O
represent -X- _ O
a -X- _ O
serious -X- _ O
public -X- _ O
health -X- _ O
and -X- _ O
economic -X- _ O
problem -X- _ O
, -X- _ O
which -X- _ O
are -X- _ O
most -X- _ O
effectively -X- _ O
prevented -X- _ O
through -X- _ O
vaccination. -X- _ O
However -X- _ O
, -X- _ O
influenza -X- _ O
viruses -X- _ O
undergo -X- _ O
continual -X- _ O
antigenic -X- _ O
variation -X- _ O
, -X- _ O
which -X- _ O
requires -X- _ O
either -X- _ O
the -X- _ O
annual -X- _ O
reformulation -X- _ O
of -X- _ O
seasonal -X- _ O
influenza -X- _ O
vaccines -X- _ O
or -X- _ O
the -X- _ O
rapid -X- _ O
generation -X- _ O
of -X- _ O
vaccines -X- _ O
against -X- _ O
potential -X- _ O
pandemic -X- _ O
virus -X- _ O
strains. -X- _ O
The -X- _ O
segmented -X- _ O
nature -X- _ O
of -X- _ O
influenza -X- _ O
virus -X- _ O
allows -X- _ O
for -X- _ O
the -X- _ O
reassortment -X- _ O
between -X- _ O
two -X- _ O
or -X- _ O
more -X- _ O
viruses -X- _ O
within -X- _ O
a -X- _ O
co-infected -X- _ O
cell -X- _ O
, -X- _ O
and -X- _ O
this -X- _ O
characteristic -X- _ O
has -X- _ O
also -X- _ O
been -X- _ O
harnessed -X- _ O
in -X- _ O
the -X- _ O
laboratory -X- _ O
to -X- _ O
generate -X- _ O
reassortant -X- _ O
viruses -X- _ O
for -X- _ O
their -X- _ O
use -X- _ O
as -X- _ O
either -X- _ O
inactivated -X- _ B-Intervention
or -X- _ I-Intervention
live-attenuated -X- _ I-Intervention
influenza -X- _ I-Intervention
vaccines. -X- _ I-Intervention
With -X- _ O
the -X- _ O
implementation -X- _ O
of -X- _ O
plasmid-based -X- _ B-Intervention
reverse -X- _ I-Intervention
genetics -X- _ I-Intervention
techniques -X- _ I-Intervention
, -X- _ O
it -X- _ O
is -X- _ O
now -X- _ O
possible -X- _ O
to -X- _ O
engineer -X- _ O
recombinant -X- _ O
influenza -X- _ O
viruses -X- _ O
entirely -X- _ O
from -X- _ O
full-length -X- _ O
complementary -X- _ O
DNA -X- _ O
copies -X- _ O
of -X- _ O
the -X- _ O
viral -X- _ O
genome -X- _ O
by -X- _ O
transfection -X- _ O
of -X- _ O
susceptible -X- _ O
cells. -X- _ O
These -X- _ O
reverse -X- _ O
genetics -X- _ O
systems -X- _ O
have -X- _ O
provided -X- _ O
investigators -X- _ O
with -X- _ O
novel -X- _ O
and -X- _ O
powerful -X- _ O
approaches -X- _ O
to -X- _ O
answer -X- _ O
important -X- _ O
questions -X- _ O
about -X- _ O
the -X- _ O
biology -X- _ O
of -X- _ O
influenza -X- _ O
viruses -X- _ O
, -X- _ O
including -X- _ O
the -X- _ O
function -X- _ O
of -X- _ O
viral -X- _ O
proteins -X- _ O
, -X- _ O
their -X- _ O
interaction -X- _ O
with -X- _ O
cellular -X- _ O
host -X- _ O
factors -X- _ O
and -X- _ O
the -X- _ O
mechanisms -X- _ O
of -X- _ O
influenza -X- _ O
virus -X- _ O
transmission -X- _ O
and -X- _ O
pathogenesis. -X- _ O
In -X- _ O
addition -X- _ O
, -X- _ O
reverse -X- _ B-Outcome
genetics -X- _ I-Outcome
techniques -X- _ I-Outcome
have -X- _ I-Outcome
allowed -X- _ I-Outcome
the -X- _ I-Outcome
generation -X- _ I-Outcome
of -X- _ I-Outcome
recombinant -X- _ I-Outcome
influenza -X- _ I-Outcome
viruses -X- _ I-Outcome
, -X- _ O
providing -X- _ O
a -X- _ O
powerful -X- _ O
technology -X- _ O
to -X- _ O
develop -X- _ O
both -X- _ O
inactivated -X- _ O
and -X- _ O
live-attenuated -X- _ O
influenza -X- _ O
vaccines. -X- _ O
In -X- _ O
this -X- _ O
review -X- _ O
, -X- _ O
we -X- _ O
will -X- _ O
summarize -X- _ O
the -X- _ O
current -X- _ O
knowledge -X- _ O
of -X- _ O
state-of-the-art -X- _ B-Outcome
, -X- _ I-Outcome
plasmid-based -X- _ I-Outcome
, -X- _ I-Outcome
influenza -X- _ I-Outcome
reverse -X- _ I-Outcome
genetics -X- _ I-Outcome
approaches -X- _ I-Outcome
and -X- _ I-Outcome
their -X- _ I-Outcome
implementation -X- _ I-Outcome
to -X- _ I-Outcome
provide -X- _ I-Outcome
rapid -X- _ I-Outcome
, -X- _ I-Outcome
convenient -X- _ I-Outcome
, -X- _ I-Outcome
safe -X- _ I-Outcome
and -X- _ I-Outcome
more -X- _ I-Outcome
effective -X- _ I-Outcome
influenza -X- _ I-Outcome
inactivated -X- _ I-Outcome
or -X- _ I-Outcome
live-attenuated -X- _ I-Outcome
vaccines -X- _ I-Outcome
. -X- _ O

